Creating new ways to live.
Nippon Shinyaku Co., Ltd. (nippon-shinyaku.co.jp) earns a Brand Analyzer score of 46 out of 100, placing it in the Early Stage tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Nippon Shinyaku Co., Ltd. ranks in the 2nd percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 78/100, Digital Presence 14/100, Visual Identity 73/100, Messaging Clarity 100/100, Trust Foundation 27/100, AI Discoverability 43/100, Brand Authority 29/100.
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company founded in 1919 and headquartered in Kyoto Prefecture, Japan. The company develops medicines and functional foods, focusing on intractable and difficult-to-treat diseases using proprietary technologies. Its mission is to enable all people to live happily by confronting rare and serious conditions. The company also engages with patients, families, shareholders, and the general public regarding its clinical research and corporate vision.
| Brand Name | Nippon Shinyaku Co., Ltd. |
|---|---|
| Domain | nippon-shinyaku.co.jp |
| Industry | Healthcare |
| Founded | 1919 |
| Headquarters | Kyoto Prefecture |
| Main Competitors | Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai, Ono Pharmaceutical, Kyowa Kirin |
Moz Domain Authority 44/100 vs category average 29 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #656,541 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "日本新薬は「生きる」ということに本気で向き合ってきました。すべての人々が、幸せに“生きる”ために、独自技術で難病に挑んでいます。先がみえないいま、必要とされているのは、新しい幸せのカタチ、生き方の探求です。" (Meta description too short (1 words). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram; no detected presence on YouTube, X (Twitter), LinkedIn, Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Nippon Shinyaku Co., Ltd. scores 34/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Nippon Shinyaku Co., Ltd. has a weak AI-visibility profile at 34/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (61/100) and its weakest is trust (19/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #656,541 (Tranco) and a Moz Domain Authority of 44/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Nippon Shinyaku Co., Ltd.'s main competitors include Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai, Ono Pharmaceutical. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Popular alternatives to Nippon Shinyaku Co., Ltd. include Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai, Ono Pharmaceutical. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company founded in 1919 and headquartered in Kyoto Prefecture, Japan. It operates in the healthcare sector with a focus on developing treatments for intractable and difficult-to-treat diseases. The company's mission centers on enabling all people to live happily through the application of unique and proprietary technologies in drug development.
Nippon Shinyaku Co., Ltd. has limited AI-search visibility, scoring 34/100 on Brand Analyzer's AI visibility composite (visibility 28, trust 19, recommendation 61). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Nippon Shinyaku Co., Ltd. was founded in 1919. Nippon Shinyaku Co., Ltd. operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Nippon Shinyaku Co., Ltd. is headquartered in Kyoto Prefecture. Nippon Shinyaku Co., Ltd. operates in the Healthcare category.
Sources: Wikidata
Nippon Shinyaku Co., Ltd. and Takeda Pharmaceutical are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Nippon Shinyaku Co., Ltd. scores 61/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
According to the available information, Nippon Shinyaku Co., Ltd. develops medicines and functional foods. The company's product efforts are specifically directed toward addressing intractable and difficult-to-treat diseases using proprietary technologies. Specific product names or therapeutic categories are not detailed in the known facts provided.
Nippon Shinyaku Co., Ltd. is known for confronting intractable diseases through innovative, proprietary technologies. The company inherits a long legacy of drug creation dating back to its founding in 1919 and is recognized for its dedication to developing medicines and functional foods aimed at rare and difficult conditions. Its mission of pursuing new forms of happiness and living distinguishes its corporate identity.
Nippon Shinyaku Co., Ltd. can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Nippon Shinyaku Co., Ltd.'s primary audience includes patients with intractable diseases and their families, who are the direct beneficiaries of its pharmaceutical and functional food products. The company also targets shareholders and the general public who may be interested in its clinical trials, corporate mission, and vision for improving quality of life through innovative medicines.
Nippon Shinyaku Co., Ltd. is recognized within Japan's pharmaceutical industry for its focus on intractable diseases and its use of proprietary technologies developed over more than a century. Its mission-driven approach - enabling all people to live happily - and its development of both medicines and functional foods contribute to its profile among patients with rare conditions, their families, and healthcare stakeholders.
Ranked closest to Nippon Shinyaku Co., Ltd.: Natural Body Wisdom (46/100), Lattice Biologics (46/100), SOPEO NOW (46/100), Tetra Bio-Pharma (46/100).
A step up - brands to learn from: Werskincare (56/100), Virtue TCM 醫道閣 (56/100).
Category leader: Dassault Systèmes (95/100).